118 related articles for article (PubMed ID: 31445192)
1. Novel conjugates with dual suppression of glutathione S-transferases and tryptophan-2,3-dioxygenase activities for improving hepatocellular carcinoma therapy.
Hua S; Wang X; Chen F; Gou S
Bioorg Chem; 2019 Nov; 92():103191. PubMed ID: 31445192
[TBL] [Abstract][Full Text] [Related]
2. Pt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immunomodulators.
Hua S; Chen F; Wang X; Wang Y; Gou S
J Inorg Biochem; 2019 Jun; 195():130-140. PubMed ID: 30952082
[TBL] [Abstract][Full Text] [Related]
3. The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma.
Liu Q; Hua S; Wang X; Chen F; Gou S
Cancer Immunol Immunother; 2021 Feb; 70(2):497-508. PubMed ID: 32840656
[TBL] [Abstract][Full Text] [Related]
4. Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase.
Hua S; Chen F; Gou S
Eur J Med Chem; 2020 Feb; 187():111949. PubMed ID: 31830637
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase.
Hua S; Chen F; Xu G; Gou S
Eur J Med Chem; 2019 May; 169():29-41. PubMed ID: 30852385
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors.
Schramme F; Crosignani S; Frederix K; Hoffmann D; Pilotte L; Stroobant V; Preillon J; Driessens G; Van den Eynde BJ
Cancer Immunol Res; 2020 Jan; 8(1):32-45. PubMed ID: 31806638
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.
Cui G; Lai F; Wang X; Chen X; Xu B
Eur J Med Chem; 2020 Feb; 188():111985. PubMed ID: 31881488
[TBL] [Abstract][Full Text] [Related]
8. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
[TBL] [Abstract][Full Text] [Related]
9. Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation.
Aboomar NM; Essam O; Hassan A; Bassiouny AR; Arafa RK
Sci Rep; 2024 Apr; 14(1):9386. PubMed ID: 38653790
[TBL] [Abstract][Full Text] [Related]
10. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and molecular modeling of new benzimidazoles as glutathione S-transferase inhibitors and anticancer agents.
Abd El-Karim SS; Anwar MM; Zaki ER; Elseginy SA; Nofal ZM
Future Med Chem; 2018 Jan; 10(2):157-181. PubMed ID: 29235906
[TBL] [Abstract][Full Text] [Related]
12. Evading immunity: new enzyme implicated in cancer.
Garber K
J Natl Cancer Inst; 2012 Mar; 104(5):349-52. PubMed ID: 22349199
[No Abstract] [Full Text] [Related]
13. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.
Novikov O; Wang Z; Stanford EA; Parks AJ; Ramirez-Cardenas A; Landesman E; Laklouk I; Sarita-Reyes C; Gusenleitner D; Li A; Monti S; Manteiga S; Lee K; Sherr DH
Mol Pharmacol; 2016 Nov; 90(5):674-688. PubMed ID: 27573671
[TBL] [Abstract][Full Text] [Related]
14.
Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
Liu Q; Liu Z; Hua W; Gou S
J Med Chem; 2021 Feb; 64(3):1701-1712. PubMed ID: 33529017
[TBL] [Abstract][Full Text] [Related]
16. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Dolusić E; Larrieu P; Moineaux L; Stroobant V; Pilotte L; Colau D; Pochet L; Van den Eynde B; Masereel B; Wouters J; Frédérick R
J Med Chem; 2011 Aug; 54(15):5320-34. PubMed ID: 21726069
[TBL] [Abstract][Full Text] [Related]
17. An inhibitor of glutathione S-transferase omega 1 that selectively targets apoptotic cells.
Pace NJ; Pimental DR; Weerapana E
Angew Chem Int Ed Engl; 2012 Aug; 51(33):8365-8. PubMed ID: 22777685
[No Abstract] [Full Text] [Related]
18. Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase.
Pantouris G; Mowat CG
Biochem Biophys Res Commun; 2014 Jan; 443(1):28-31. PubMed ID: 24269239
[TBL] [Abstract][Full Text] [Related]
19. A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells.
Turella P; Filomeni G; Dupuis ML; Ciriolo MR; Molinari A; De Maria F; Tombesi M; Cianfriglia M; Federici G; Ricci G; Caccuri AM
J Biol Chem; 2006 Aug; 281(33):23725-32. PubMed ID: 16769721
[TBL] [Abstract][Full Text] [Related]
20. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
